A private inbox doesn’t have to come with a price tag—or a catch. Proton Mail’s free plan gives you the privacy and security you expect, without selling your data or showing you ads.

Built by scientists and privacy advocates, Proton Mail uses end-to-end encryption to keep your conversations secure. No scanning. No targeting. No creepy promotions.

With Proton, you’re not the product — you’re in control.

Start for free, or upgrade for 60% off this Black Friday. Stay private always.

Get encrypted private email

FDA answers lawmakers on psychedelic trials, DEA boosts MDMA and ibogaine quotas, Massachusetts waives doctor mandates for veterans, and DEA stay lifts

By Jack Gorsline

In this week's edition of PSA’s Weekly Psychedelic Policy Briefing, Psychedelic State(s) of America Founder and Investigative Journalist Jack Gorsline examines four defining institutional developments across federal drug evaluation standards, manufacturing quotas, state access models, and administrative rescheduling jurisprudence. First, the Food and Drug Administration (FDA) clarified the regulatory limits of Special Protocol Assessments to Congress amid an accelerating approval race between Usona Institute and Compass Pathways. Second, the Drug Enforcement Administration (DEA) proposed substantial 2027 manufacturing quota increases for MDMA and ibogaine to support expanding clinical trials and implement presidential directives under the Right to Try Act. Third, the Massachusetts State Senate passed landmark legislation allowing military veterans to qualify for medical cannabis without a physician certification, creating a self-certification model to bypass federal prescribing restrictions. Finally, the temporary administrative stay in Docket DEA-2024-0059 expired on November 5 following final reply briefs on the GAO watchdog audit (GAO-26-108623), setting Chief ALJ Derek Julius to certify the evidentiary record for the DEA Administrator.

The Food and Drug Administration (FDA) issued formal written responses to inquiries from the bipartisan Congressional Psychedelics Caucus concerning regulatory standards for psychedelic clinical investigations, as reported by Psychedelic Alpha.

In its communication, the agency addressed key friction points that have emerged across the sector, including functional unblinding in clinical trials, the role of mandatory psychotherapy protocols, and the binding nature of Special Protocol Assessments (SPAs). The FDA clarified that while an SPA creates a binding agreement between the agency and a sponsor regarding trial design endpoints, size, and statistical analysis plans, it does not guarantee marketing approval. The agency emphasized that an SPA agreement does not preclude an independent FDA Advisory Committee from scrutinizing trial execution, participant safety data, or therapeutic context during the final New Drug Application (NDA) review.

The clarification provides vital guidance for late-stage psychedelic developers, including Compass Pathways and Usona Institute, as sponsors navigate the boundary between drug pharmacology and mandatory clinical care models.

As examined in a Psychedelic State(s) of America investigation syndicated by DoubleBlind, the back-to-back regulatory milestones from nonprofit Usona Institute and commercial developer Compass Pathways highlight a stark divide between competing clinical and economic models. On November 2, Usona reportedly submitted its New Drug Application (NDA) to the FDA for PSIL201 in Major Depressive Disorder (MDD), an unconfirmed filing first reported by Psychedelic Alpha that triggered a single-day 28% drop in Compass share prices before Compass announced on November 3 that it would finalize its own COMP360 NDA for Treatment-Resistant Depression (TRD) within two weeks, which was subsequently completed and announced by Compass on November 9.

While Compass backs COMP360 with the largest randomized, double-blind clinical program in psilocybin history across two pivotal Phase 3 trials (COMP005 and COMP006)—demonstrating a durable reduction in depression scores for 39% of two-dose participants at 26 weeks—company executives have signaled plans to benchmark annualized pricing to Johnson & Johnson's Spravato at roughly $50,000 to $65,000 per patient per year. Assuming an average regimen of three administrations annually, single doses of COMP360 are projected to cost between $18,000 and $22,000 prior to multi-hour clinical supervision fees. Conversely, Usona operates as a 501(c)(3) medical research organization without restrictive Orange Book patent barriers, positioning PSIL201 to potentially undercut commercial pricing under a broader MDD indication, though the nonprofit lacks an established commercial sales force and would likely require a distribution partner to scale patient access.

In a significant administrative move reflecting surging biomedical interest in entheogenic medicine, the Drug Enforcement Administration published its proposed 2027 Aggregate Production Quotas (APQs) in the Federal Register on Tuesday, November 10, 2026 (Federal Register Document 2026-22843), as detailed by Marijuana Moment.

Under the proposed rule, the DEA is requesting higher manufacturing limits for two prominent Schedule I controlled substances: 3,4-methylenedioxymethamphetamine (MDMA) and ibogaine. The agency explained that increased production allocations are necessary to support clinical trials evaluating the compounds for post-traumatic stress disorder, treatment-resistant depression, and opioid use disorder. Crucially, the DEA explicitly tied these quota increases to two binding presidential executive orders: Executive Order 14379 ("Addressing Addiction through the Great American Recovery Initiative"), which directs federal agencies to prioritize novel non-opioid recovery modalities, and Executive Order 14401 ("Accelerating Medical Treatments for Serious Mental Illness"), which specifically mandates that federal agencies establish functional access pathways for eligible patients seeking investigational psychedelic medicines, including ibogaine compounds, under the federal Right to Try Act (21 U.S.C. § 360bbb-0a).

The agency's formal incorporation of Executive Order 14401 represents a major bureaucratic pivot. Historically, DEA quota notices restricted production strictly to domestic academic protocols holding active FDA Investigational New Drug (IND) approvals. By recognizing clinical supply obligations under Right to Try authorities, the agency is formally acknowledging therapeutic access channels outside traditional randomized clinical trials.

Simultaneously, the notice previewed separate aggregate quota adjustments for botanical cannabis, preparing the administrative groundwork to accommodate anticipated Schedule III manufacturing transfers once final administrative rulemaking concludes.

In state policy reform, the Massachusetts State Senate passed pioneering legislation on November 6, 2026, containing landmark provisions that authorize military veterans to enroll in the state medical cannabis program without obtaining a written recommendation from a licensed physician, as reported by Marijuana Moment.

The measure, which advanced through the legislature following the decisive voter rejection of Question 8 on Election Day, directly confronts a persistent structural dilemma in veterans healthcare. Under current federal policy, physicians employed by the U.S. Department of Veterans Affairs (VA) are strictly prohibited from prescribing, recommending, or completing state-mandated paperwork for Schedule I or state-regulated substances. As a result, veterans seeking therapeutic relief for service-connected conditions have been forced to pay private doctors out-of-pocket consulting fees, often exceeding several hundred dollars, simply to obtain state registry certifications.

Under the Senate bill, eligible military veterans presenting documented proof of military service and qualifying conditions, such as post-traumatic stress disorder, chronic pain, or traumatic brain injury, can register directly with the Massachusetts Cannabis Control Commission without a physician sign-off. Additionally, the legislation expands the broader list of qualifying medical conditions for non-veteran patients and mandates increased state coordination regarding veteran suicide prevention initiatives.

Policy analysts emphasize that Massachusetts' self-certification mechanism represents an important precedent for emerging state-level natural medicine programs. With several states currently developing regulated access pathways for psilocybin and plant medicines, the Massachusetts veteran exemption model offers a viable legislative solution to insulate veterans from federal health administration penalties while lowering financial barriers to evidence-based therapeutic access.

A critical juncture was reached in federal administrative drug classification on Thursday, November 5, 2026, as all registered participants submitted final reply briefs before DEA Chief Administrative Law Judge Derek Julius in Docket DEA-2024-0059, concluding the formal briefing schedule and expiring the temporary stay on proceedings, as reported by Marijuana Moment.

The briefing focused on the evidentiary weight and administrative fallout of a September 2026 audit released by the Government Accountability Office (GAO-26-108623). The GAO report revealed widespread irregularities within the DEA Office of Diversion Control, including unwritten scheduling evaluation criteria, arbitrary timeline enforcement, and undocumented communications with Department of Justice officials. In its final brief, the DEA maintained that the GAO report should receive zero evidentiary weight in determining whether to transfer the substance from Schedule I to Schedule III, with agency counsel arguing that the audit addressed general internal management protocols rather than the specific scientific and medical evaluations conducted by the Department of Health and Human Services (HHS) and the FDA. Conversely, rescheduling opponents asserted that the administrative deficiencies documented by the GAO undermine the procedural integrity of the entire rulemaking process, arguing that the absence of formal written rulebooks violates Section 553 of the Administrative Procedure Act (APA) and renders any ensuing scheduling decision arbitrary and capricious. With the November 5 deadline passed, the administrative stay has lifted by its own terms, leaving Chief Judge Julius to review the complete 2,500-page evidentiary record, the admitted GAO report, and party briefs to prepare his formal, non-binding recommendation for DEA Administrator Terrance C. Cole.

The resolution of Docket DEA-2024-0059 holds immediate operational relevance for the psychedelic ecosystem. Under 21 U.S.C. § 811(j), when the FDA approves the first New Drug Applications for synthetic psilocybin or MDMA, the DEA is statutorily required to issue an interim final rule transferring the approved products out of Schedule I within 90 days. The legal standards established in Judge Julius's forthcoming recommendation regarding agency documentation, inter-agency deference to HHS, and the admissibility of procedural audits will define how the DEA handles post-approval rescheduling for psychedelic medicines in 2027.

Psychedelic State(s) of America is an independent, non-partisan investigative journalism initiative. Funding is provided via reader subscriptions and philanthropic research grants. The reporting presented in this briefing does not constitute medical, legal, or investment advice. Primary source dockets, statutory texts, and regulatory filings are verified independently through official government registries, including the Federal Register, FDA Dockets, and court records.

Until next time,

The Psychedelic State(s) of America Team